UTSW/Children's Medical Center Trials

UTSW/Children's Medical Center	Welcome, Profile Billing Logout

52 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Magenau, John

Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting

174

Orca-T, Standard-of-Care, SOC

Orca Biosystems, Inc.

Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome

07/24

07/26

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting

1/2

VCAR33

Vor Biopharma

Leukemia, Myeloid, Acute

10/25

11/26

Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting

255

Orca-T

Orca Biosystems, Inc.

Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia

07/24

07/26

Laetsch, Theodore

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

NCT03213678: Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Completed

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, FDG-Positron Emission Tomography, FDG, FDG-PET, FDG-PET Imaging, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Samotolisib, 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-, LY 3023414, LY-3023414, LY3023414, WHO 10889, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor

09/23

12/24

NCT05668962: Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Recruiting

Selpercatinib, Retevmo, Sodium Iodine I-131, I-131, I-131 NaI, rhTSH, thyrotropin alfa

Massachusetts General Hospital, Eli Lilly and Company

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer

03/25

01/26

NETTER-P, NCT04711135 / 2020-002951-39: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Active, not recruiting

Europe, US

Lutetium [177Lu] oxodotreotide/dotatate, Lutathera

Advanced Accelerator Applications

Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma

03/24

05/29

ADVL1823, NCT03834961: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Active, not recruiting

Canada, US

Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi

Children's Oncology Group, National Cancer Institute (NCI)

Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm

09/24

11/25

RAISE, NCT06458036: Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer

Recruiting

Selpercatinib Monotherapy, 131I Therapy

Children's Hospital of Philadelphia, Eli Lilly and Company, United States Department of Defense

Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid

11/30

11/31

NCT03213704: Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Active, not recruiting

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma

09/24

10/25

NCT03213652: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Active, not recruiting

Canada, US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ensartinib, X 396, X-396, X396, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI), Children's Oncology Group

Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor

06/25

NCT05783323: Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Recruiting

Larotrectinib monotherapy, 131I therapy

Children's Hospital of Philadelphia, Bayer

Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid

10/26

10/27

NCT04195555: Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Active, not recruiting

US, RoW

Ivosidenib, AG 120, AG-120, AG120, Tibsovo

National Cancer Institute (NCI), Children's Oncology Group

Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor

06/25

CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting

105

Europe, Japan, US, RoW

Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide

Eli Lilly and Company

Neoplasms, Child, Adolescent

05/27

ARAR2221, NCT06064097: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Recruiting

Canada, US

Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Radiography, Chest X-ray, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Electronic Health Record Review, Fluciclovine F18, (18F)Fluciclovine, (18F)GE-148, 18F-Fluciclovine, [18F]FACBC, Anti-(18f)FABC, Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid, Anti-[18F] FACBC, Axumin, Fluciclovine (18F), FLUCICLOVINE F-18, GE-148 (18F), GE-148 F-18, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8

12/26

MATCH, NCT03155620: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric Screening Trial)

Active, not recruiting

2316

Canada, US, RoW

Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ensartinib, X 396, X-396, X396, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Laboratory Biomarker Analysis, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mutation Carrier Screening, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Samotolisib, 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-, LY 3023414, LY-3023414, LY3023414, WHO 10889, Selpercatinib, LOXO 292, LOXO-292, LOXO292, RET Kinase Inhibitor LOXO-292, Retevmo, Retsevmo, WHO 10967, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Tazemetostat, E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438, Tipifarnib, R115777, Zarnestra, Ulixertinib, BVD-523, VRT752271, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX 4032, PLX-4032, PLX4032, RG 7204, RG-7204, RG7204, RO 5185426, RO-5185426, Zelboraf, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor

06/25

NCT04284774: Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Active, not recruiting

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Tipifarnib, R115777, Zarnestra

National Cancer Institute (NCI)

Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma

03/24

04/25

NCT04320888: Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Active, not recruiting

US, RoW

Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Selpercatinib, LOXO 292, LOXO-292, LOXO292, RET Kinase Inhibitor LOXO-292, Retevmo, Retsevmo, WHO 10967, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI), Children's Oncology Group

Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor

09/24

10/25

NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed

1/2

Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine

Hutchmed, HUTCHMED Limited

Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

04/23

PEPN2112, NCT05071209: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Active, not recruiting

1/2

Canada, US

Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344

National Cancer Institute (NCI)

Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm

09/24

11/25

BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting

1/2

300

US, RoW

CAB-AXL-ADC, PD-1 inhibitor

BioAtla, Inc.

Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma

01/25

NCT04796012: VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors

Recruiting

1/2

Atezolizumab, Tecentriq, Vincristine, Vincristine Sulfate Injection, Oncovin, Vincasar PES, Vincrex, Irinotecan, Irinotecan Hydrochloride Injection, Campto, Temozolomide, Temozolomide Capsules, Temodar

University of Texas Southwestern Medical Center

Solid Tumor, Rhabdomyosarcoma

01/27

NCT05286801: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Recruiting

1/2

Canada, US, RoW

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Tiragolumab, MTIG7192A, RG6058, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor

06/26

LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting

1/2

Lurbinectedin

Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer

Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma

07/26

07/28

CARE study, NCT04094610 / 2019-003055-11: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

	Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
	Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
	Oct 2021 - Oct 2021: Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021

Recruiting

1/2

Europe, Canada, US, RoW

Oral repotrectinib (TPX-0005), Oral repotrectinib (TPX-0005) capsules, Oral repotrectinib (TPX-0005) oral suspension, repotrectinib

Turning Point Therapeutics, Inc., Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb Company)

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors

09/26

09/27

NCT05642455: SPEARHEAD-3 Pediatric Study

Recruiting

1/2

Afamitresgene autoleucel

Adaptimmune

Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma

10/26

07/38

TINKS, NCT05634369: A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Recruiting

1/2

GEM/DOX + TGFBi expanded NK cells, Docetaxel, Dexamethasone, Pegfilgrastim, Gemcitabine

Nationwide Children's Hospital, National Pediatric Cancer Foundation

Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed

12/26

12/27

NCT04870944: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recruiting

1/2

US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, FACT Complex-targeting Curaxin CBL0137, CBL0137

Children's Oncology Group, Incuron LLC, National Cancer Institute (NCI)

Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm

12/26

PEPN2011, NCT04851119: Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Recruiting

1/2

147

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Dual X-ray Absorptiometry, BMD scan, bone mineral density scan, DEXA, DEXA (Bone Density), DEXA Scan, dual energy x-ray absorptiometric scan, Dual Energy X-ray Absorptiometry, Dual X-Ray Absorptometry, DXA, DXA SCAN, Tegavivint, BC 2059, BC-2059, BC2059, Tegatrabetan, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

Children's Oncology Group, National Cancer Institute (NCI)

Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor

06/28

NCT06156410: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Recruiting

Cabozantinib

Children's Hospital of Philadelphia, Children's Hospital Colorado, Alex's Lemonade Stand Foundation, Exelixis

Ewing Sarcoma, Osteosarcoma

11/27

11/28

NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting

321

Europe, US

INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide

Inhibrx Biosciences, Inc

Colorectal Adenocarcinoma, Ewing Sarcoma

06/26

12/26

NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting

250

Europe, Canada, US, RoW

ADP adoptive cell therapy

Adaptimmune

Neoplasms

04/32

NCT04539366: Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial

Suspended

Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography Test, EC, Echocardiography, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, GD2-CAR-expressing Autologous T-lymphocytes, tvs-CTL Vaccine, Imaging Procedure, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), Imaging Procedures, Imaging Technique, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Magnetic Resonance Imaging of the Heart, Cardiac MRI, Heart MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration

National Cancer Institute (NCI)

Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma

12/40

NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available

N/A

Canada, US, RoW

CTL019, tisagenlecleucel, Kymriah

Novartis Pharmaceuticals

Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)

PEPN22P1, NCT05359237: Vincristine Pharmacokinetics in Infants

Recruiting

N/A

Canada, US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Vincristine, LCR, Leurocristine, VCR, Vincrystine

Children's Oncology Group, National Cancer Institute (NCI)

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

12/25

NCT05020951: Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE

Active, not recruiting

N/A

118

Medidata RAVE

Children's Oncology Group, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium

Accurate and Complete Data Acquisition for Clinical Trials

07/23

09/25

NCT05910307: Synovial Sarcoma Registry / Biospecimen Repository

Recruiting

N/A

1000

Children's Hospital of Philadelphia

Synovial Sarcoma

06/28

06/33

NCT05024929: Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Recruiting

N/A

US, RoW

Whole body scan

Children's Hospital of Philadelphia, United States Department of Defense

Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer

02/31

02/33

Bachanova, Veronika

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

NCT03125642: Auto Stem Cell Transplant for Lymphoma Patients

Recruiting

150

Etoposide, VP-16, BCNU, Carmustine, AraC, Cytarabine, cytosine arabinoside, Cytosar-U, Depocyt, Melphalan, Alkeran, Peripheral blood stem cell transplantation, PBSC, G-CSF, filgrastim, Cyclophosphamide, Cytoxan, Total Body Irradiation, TBI

Masonic Cancer Center, University of Minnesota

Non-Hodgkin Lymphoma, Hodgkin Lymphoma

09/25

04/26

NCT03642626: MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruiting

144

KYMRIAH, tisagenlecleucel, YESCARTA, Fludarabine 30mg/m2 4 doses, Cyclophosphamide 500 mg/m2; 2 doses, Fludarabine 30mg/m2 3 doses, Cyclophosphamide 500 mg/m2; 3 doses, Fludarabine 25mg/m2 3 days, Cyclophosphamide 250 mg/m2; 3 days, Tecartus, Brexucabtagene Autoleucel, Abecma, Intravenous Suspension, Cyclophosphamide 900 mg/m2; 1 day, Breyanzi Injectable Product

Masonic Cancer Center, University of Minnesota

Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

02/24

06/28

BTCRC-HEM15-027, NCT03681561: Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting

1/2

Ruxolitinib, Jakafi, Nivolumab, Opdivo

Veronika Bachanova, Incyte Corporation, Bristol-Myers Squibb

Hodgkin Lymphoma

07/25

07/27

NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated

1/2

GDA-201, Nicotinamide (NAM) NK

Gamida Cell ltd

Non-Hodgkin Lymphoma

04/24

NCT04855253: Study of E7777 Prior to Kymriah for R/R DLBCL

Recruiting

1/2

E7777

Masonic Cancer Center, University of Minnesota

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma

12/25

NCT05114837: Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Withdrawn

1/2

allogeneic CAR19 regulatory T cells (CAR19-tTreg), Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN

Masonic Cancer Center, University of Minnesota

Lymphoma Leukemia

08/28

NCT04555811: FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Completed

FT596, Rituximab, Rituxan

Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)

NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma

02/23

11/23

NCT06414278: Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

Recruiting

N/A

Non-Interventional Study

Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

07/27

02/28

Patterson, Alison

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

NCT02013336: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Recruiting

MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

South Plains Oncology Consortium

Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma

12/23

NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Available

N/A

ONC201 (dordaviprone)

Chimerix

Glioma, H3 K27M

Tucker, Michelle Smith

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Magenau, John

Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting

174

Orca-T, Standard-of-Care, SOC

Orca Biosystems, Inc.

Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome

07/24

07/26

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting

1/2

VCAR33

Vor Biopharma

Leukemia, Myeloid, Acute

10/25

11/26

Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting

255

Orca-T

Orca Biosystems, Inc.

Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia

07/24

07/26

Laetsch, Theodore

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

Completed

National Cancer Institute (NCI)

09/23

12/24

NCT05668962: Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Recruiting

Selpercatinib, Retevmo, Sodium Iodine I-131, I-131, I-131 NaI, rhTSH, thyrotropin alfa

Massachusetts General Hospital, Eli Lilly and Company

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer, Follicular Thyroid Cancer, Unresectable Thyroid Gland Carcinoma, Papillary Thyroid Cancer

03/25

01/26

NETTER-P, NCT04711135 / 2020-002951-39: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Active, not recruiting

Europe, US

Lutetium [177Lu] oxodotreotide/dotatate, Lutathera

Advanced Accelerator Applications

Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma

03/24

05/29

ADVL1823, NCT03834961: Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

Active, not recruiting

Canada, US

Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi

Children's Oncology Group, National Cancer Institute (NCI)

Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm

09/24

11/25

RAISE, NCT06458036: Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer

Recruiting

Selpercatinib Monotherapy, 131I Therapy

Children's Hospital of Philadelphia, Eli Lilly and Company, United States Department of Defense

Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid

11/30

11/31

NCT03213704: Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Active, not recruiting

National Cancer Institute (NCI)

09/24

10/25

Active, not recruiting

Canada, US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ensartinib, X 396, X-396, X396, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI), Children's Oncology Group

06/25

NCT05783323: Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Recruiting

Larotrectinib monotherapy, 131I therapy

Children's Hospital of Philadelphia, Bayer

Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid

10/26

10/27

NCT04195555: Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Active, not recruiting

US, RoW

Ivosidenib, AG 120, AG-120, AG120, Tibsovo

National Cancer Institute (NCI), Children's Oncology Group

06/25

CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting

105

Europe, Japan, US, RoW

Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide

Eli Lilly and Company

Neoplasms, Child, Adolescent

05/27

ARAR2221, NCT06064097: A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Recruiting

Canada, US

Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Radiography, Chest X-ray, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Electronic Health Record Review, Fluciclovine F18, (18F)Fluciclovine, (18F)GE-148, 18F-Fluciclovine, [18F]FACBC, Anti-(18f)FABC, Anti-1-Amino-3-[18F]Fluorocyclobutane-1-Carboxylic Acid, Anti-[18F] FACBC, Axumin, Fluciclovine (18F), FLUCICLOVINE F-18, GE-148 (18F), GE-148 F-18, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8

12/26

Active, not recruiting

2316

Canada, US, RoW

Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ensartinib, X 396, X-396, X396, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Laboratory Biomarker Analysis, Larotrectinib Sulfate, ARRY 470 Sulfate, LOXO 101 Sulfate, LOXO-101 Sulfate, Vitrakvi, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mutation Carrier Screening, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, PD0332991, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Samotolisib, 2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-, LY 3023414, LY-3023414, LY3023414, WHO 10889, Selpercatinib, LOXO 292, LOXO-292, LOXO292, RET Kinase Inhibitor LOXO-292, Retevmo, Retsevmo, WHO 10967, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate, Tazemetostat, E 7438, E-7438, E7438, EPZ 6438, EPZ-6438, EPZ6438, Tipifarnib, R115777, Zarnestra, Ulixertinib, BVD-523, VRT752271, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX 4032, PLX-4032, PLX4032, RG 7204, RG-7204, RG7204, RO 5185426, RO-5185426, Zelboraf, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

06/25

NCT04284774: Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Active, not recruiting

National Cancer Institute (NCI)

03/24

04/25

NCT04320888: Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Active, not recruiting

US, RoW

National Cancer Institute (NCI), Children's Oncology Group

09/24

10/25

NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed

1/2

Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine

Hutchmed, HUTCHMED Limited

Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

04/23

PEPN2112, NCT05071209: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

Active, not recruiting

1/2

Canada, US

Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344

National Cancer Institute (NCI)

09/24

11/25

BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting

1/2

300

US, RoW

CAB-AXL-ADC, PD-1 inhibitor

BioAtla, Inc.

Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma

01/25

NCT04796012: VITAS: Atezolizumab in Combination with Chemotherapy for Pediatric Relapsed/refractory Solid Tumors

Recruiting

1/2

University of Texas Southwestern Medical Center

Solid Tumor, Rhabdomyosarcoma

01/27

NCT05286801: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Recruiting

1/2

Canada, US, RoW

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Tiragolumab, MTIG7192A, RG6058, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

06/26

LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting

1/2

Lurbinectedin

Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer

Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma

07/26

07/28

CARE study, NCT04094610 / 2019-003055-11: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

	Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
	Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
	Oct 2021 - Oct 2021: Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021

Recruiting

1/2

Europe, Canada, US, RoW

Oral repotrectinib (TPX-0005), Oral repotrectinib (TPX-0005) capsules, Oral repotrectinib (TPX-0005) oral suspension, repotrectinib

Turning Point Therapeutics, Inc., Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb Company)

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors

09/26

09/27

NCT05642455: SPEARHEAD-3 Pediatric Study

Recruiting

1/2

Afamitresgene autoleucel

Adaptimmune

Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma

10/26

07/38

Recruiting

1/2

GEM/DOX + TGFBi expanded NK cells, Docetaxel, Dexamethasone, Pegfilgrastim, Gemcitabine

Nationwide Children's Hospital, National Pediatric Cancer Foundation

Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed

12/26

12/27

NCT04870944: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recruiting

1/2

US, RoW

Children's Oncology Group, Incuron LLC, National Cancer Institute (NCI)

12/26

PEPN2011, NCT04851119: Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Recruiting

1/2

147

Children's Oncology Group, National Cancer Institute (NCI)

06/28

NCT06156410: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Recruiting

Cabozantinib

Children's Hospital of Philadelphia, Children's Hospital Colorado, Alex's Lemonade Stand Foundation, Exelixis

Ewing Sarcoma, Osteosarcoma

11/27

11/28

NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting

321

Europe, US

INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide

Inhibrx Biosciences, Inc

Colorectal Adenocarcinoma, Ewing Sarcoma

06/26

12/26

NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting

250

Europe, Canada, US, RoW

ADP adoptive cell therapy

Adaptimmune

Neoplasms

04/32

Suspended

Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography Test, EC, Echocardiography, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, GD2-CAR-expressing Autologous T-lymphocytes, tvs-CTL Vaccine, Imaging Procedure, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), Imaging Procedures, Imaging Technique, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Magnetic Resonance Imaging of the Heart, Cardiac MRI, Heart MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Questionnaire Administration

National Cancer Institute (NCI)

12/40

NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available

N/A

Canada, US, RoW

CTL019, tisagenlecleucel, Kymriah

Novartis Pharmaceuticals

Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)

PEPN22P1, NCT05359237: Vincristine Pharmacokinetics in Infants

Recruiting

N/A

Canada, US, RoW

Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Vincristine, LCR, Leurocristine, VCR, Vincrystine

Children's Oncology Group, National Cancer Institute (NCI)

Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

12/25

NCT05020951: Pilot Study to Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE

Active, not recruiting

N/A

118

Medidata RAVE

Children's Oncology Group, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium

Accurate and Complete Data Acquisition for Clinical Trials

07/23

09/25

NCT05910307: Synovial Sarcoma Registry / Biospecimen Repository

Recruiting

N/A

1000

Children's Hospital of Philadelphia

Synovial Sarcoma

06/28

06/33

NCT05024929: Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Recruiting

N/A

US, RoW

Whole body scan

Children's Hospital of Philadelphia, United States Department of Defense

Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer

02/31

02/33

Bachanova, Veronika

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

NCT03125642: Auto Stem Cell Transplant for Lymphoma Patients

Recruiting

150

Masonic Cancer Center, University of Minnesota

Non-Hodgkin Lymphoma, Hodgkin Lymphoma

09/25

04/26

NCT03642626: MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruiting

144

Masonic Cancer Center, University of Minnesota

Acute Lymphoblastic Leukemia, Large B-cell Lymphoma

02/24

06/28

BTCRC-HEM15-027, NCT03681561: Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting

1/2

Ruxolitinib, Jakafi, Nivolumab, Opdivo

Veronika Bachanova, Incyte Corporation, Bristol-Myers Squibb

Hodgkin Lymphoma

07/25

07/27

NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated

1/2

GDA-201, Nicotinamide (NAM) NK

Gamida Cell ltd

Non-Hodgkin Lymphoma

04/24

NCT04855253: Study of E7777 Prior to Kymriah for R/R DLBCL

Recruiting

1/2

E7777

Masonic Cancer Center, University of Minnesota

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma

12/25

NCT05114837: Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Withdrawn

1/2

allogeneic CAR19 regulatory T cells (CAR19-tTreg), Fludarabine, FLUDARA, Cyclophosphamide, CYTOXAN

Masonic Cancer Center, University of Minnesota

Lymphoma Leukemia

08/28

NCT04555811: FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Completed

FT596, Rituximab, Rituxan

Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)

NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma

02/23

11/23

NCT06414278: Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

Recruiting

N/A

Non-Interventional Study

Masonic Cancer Center, University of Minnesota, National Cancer Institute (NCI)

Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm

07/27

02/28

Patterson, Alison

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

NCT02013336: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Recruiting

MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

South Plains Oncology Consortium

Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma

12/23

NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Available

N/A

ONC201 (dordaviprone)

Chimerix

Glioma, H3 K27M

Tucker, Michelle Smith

PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting

1400

Europe, Canada, Japan, US, RoW

Previously treated CAR-T patients

Novartis Pharmaceuticals, University of Pennsylvania

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

02/36

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites